Health Conditions

ACE Inhibitors: List, Description and Nursing interventions

ACE Inhibitors

ACE Inhibitors

ACE Inhibitors or Angiotensin converting enzymes inhibitors are also called vasoactive peptides because of their direct effect on blood vessels. ACE inhibitors are widely used medicine and first line of treatment in hypertension and congestive heart failure. ACE inhibitors decrease systemic vascular resistance without increasing heart rate and also promotes natriuresis.

List of Common ACE Inhibitors:

ACE Inhibitors list contains many important drugs extensively used nowadays, which are as follows:

GENERIC NAME BRAND NAME
Benazepril Lotensin
Captopril Capoten, Acepril, Capozide
Fosinopril Fositen, Monopril, Staril
Lisinopril Lopril, Zestrin, Prinivil, Novatec
Enalapril Vasotec, Epaned, Enap, Ranitec

 

RENIN-ANGIOTENSIN ALDOSTERONE SYSTEM (RAS):

The RAS (The renin–angiotensin system) significantly participates in pathophysiology of hypertension, congestive heart failure, myocardial infarction, diabetic nephropathy. The renin-angiotensin aldosterone system leads to produce Angiotensin II which is the most active angiotensin. Angiotensin II produce by the series of proteolytic steps. A pre enzyme Angiotensinogen produced from the liver. Angiotensinogen is acted upon by renin and converted into Angiotensin I. Renin is an enzyme released from the juxtaglomerular cells of kidney in response to low fluid moves through nephrons. Angiotensin I is further converted into Angiotensin II by the Angiotensin converted enzymes (ACE). The resulting compound Angiotensin II is responsible to increase blood pressure and retention of sodium and water from kidneys.

THREE MAJOR EFFECTS OF ANGIOTENSIN II:

The production of Angiotensin II resulted in three major effects which leads to cause different cardiopathies, increase blood pressure and nephropathy.

1. Altered Peripheral resistance

Angiotensin II increase peripheral resistance by the following mechanism:

All these above changes cause Rapid Pressor response, blood pressure increases.

2. Altered Renal function
3. Altered Cardiovascular structure

Long term Angio II release results in cardiac remodeling as follows.

MECHANISM OF ACTION:

ACE is an ectoenzyme and glycoprotein which is the main component of RAS. It coverts Angio I to Angio II which controls blood pressure by controlling the volume of body fluids in the body.

ACE inhibitors controls blood pressure by the following two steps

Firstly, ACE inhibitors inhibits the Angiotensin converting enzyme and thus inhibits the production of Angiotensin II. As a result of inhibition of Angio II, all the functions performed by Angio II stopped as a result of which ACE inhibitors decrease systemic vascular resistance without increasing heart rate.

Secondly, ACE inhibitors inhibits the degradation of Bradykinin, Substance P, enkephalin. Bradykinin is a vasoactive peptide that causes dilation of blood vessels and decrease blood pressure. ACE degrades bradykinin and increase vasoconstriction results in increase blood pressure. ACE I inhibits the degradation of bradykinin which decreases the peripheral vascular resistance thus, control the blood pressure.

PHARMACOKINETICS

All ACE inhibitors are different in their structure and pharmacokinetics, but in clinical use, they are interchangeable. Currently available ACEI are all active when given orally. ACE inhibitors are highly polar and eliminated in urine except fosinopril and moexipril. Doses should be reduced in renal insufficiency. A number of ACEI are and active (e.g. Lisinopril, captopril) while some are prodrugs (e.g. enalapril). ACE inhibitors do not penetrate the central nervous system. Many ACE inhibitors are given once daily because of longer half-life except Captopril. Lisinopril and Enalapril have half-life of 12 hours.

INDICATIONS

CONTRAINDICATIONS

SIDE EFFECTS & ADVERSE EFFECTS

ACE inhibitors are generally well tolerated but some side effects may be shown which are as follows:

DRUG INTERACTION

NURSING INTERVENTIONS

PATIENT EDUCATION

Exit mobile version